Startups

Scientist, Cell Biology

Axiom Bio · South San Francisco · On-site

← All jobs
About Axiom Bio

Axiom provides frontier intelligence for human drug toxicity, helping scientists reduce unexpected toxicity earlier and develop safer medicines with less animal testing. Backed by Amplify Partners.

About the role

Build human cell models that accurately predict drug-induced toxicity in the liver, kidney, heart, immune system, and pharmacokinetics like exposure and metabolisms. Design and optimize physiologically relevant systems using primary human cells, multicellular cultures, organoids, and other advanced models. Found on 1752vc Careers, the job board for startup and VC roles.

What they're looking for

  • Experience with primary human cell culture, iPSC culture and differentiation, and cell engineering
  • Experience developing physiologically relevant models, including co-cultures, organoids, spheroids, and engineered tissues
  • A strong foundation in cell biology, molecular biology, physiology, and pharmacology
  • Expertise in high-content imaging, Cell Painting, fluorescence microscopy, live-cell imaging, and image-based phenotypic screening
  • Experience developing, miniaturizing, and automating assays for high-throughput screening
  • Experience measuring cell viability, mitochondrial function, oxidative stress, ER stress, apoptosis, inflammation, and other functional responses
More about this role

Build human cell models and multiplexed high-content assays that reveal how drugs cause toxicity and predict their effects in people. Partner with robotics engineers, computational scientists, and ML researchers to generate large-scale biological datasets that power frontier AI agents for translational drug discovery.

Axiom’s mission is to eliminate unexpected drug toxicity and unlock an abundance of ultra safe medicines. We are starting with the liver, where toxicity remains a leading cause of drug failure. Our high-throughput human liver safety platform combines advanced human cell systems with imaging, transcriptomics, mass spectrometry, and drug metabolism measurements. Our AI agents integrate these data with chemical structure, human exposure, and thousands of clinical reference compounds to predict whether a drug will be toxic in humans, why, and how to make it safer.

We work with seven of the world’s top twenty pharmaceutical companies to design safety into molecules from the earliest stages. This applied work feeds directly into our partnerships with leading frontier AI labs, turning real discovery challenges and experimental feedback loops into scientific skill trees and...

Read the full posting on Axiom Bio's site ↗

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.